Publication|Articles|September 24, 2025

Optimizing Long-Acting Injectable Administration for Patients Living With Schizophrenia

This educational resource was sponsored by Johnson & Johnson.

In this educational resource, experts from a pharmacy and hospital provide an overview of their respective long-acting injectable antipsychotic programs, which are designed to help improve access and adherence to medications for people living with a severe and persistent mental illness like schizophrenia.

Articles in this issue

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo